American biopharmaceutical company at South San Francisco in California, founded in 2015 out of Rigel work as FLX Bio and renamed RAPT Therapeutics in 2019, listed on the Nasdaq. Develops oral small molecules that act on immune cells, with programmes in inflammatory disease including a CCR4 antagonist studied in atopic dermatitis and asthma and an anti-inflammatory antibody, and runs its own discovery chemistry and clinical development.
Keine Kommentare verfügbar.
Bewertung & Kommentar hinterlassen